Changes to This Summary (04/03/2015)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added Corrigan et al. as reference 2.
Added text about the EURO-EWING-INTERGROUP-EE99 trial, including risk classification, treatment regimens, event-free survival and overall survival rates, and toxicity (cited Le Deley et al. as reference 20 and level of evidence 1iiA).
Added text to state that in the Italian/Scandinavian experience, younger age, longer disease-free interval, and lung-only recurrence were associated with longer progression-free survival after recurrence. In this experience, patients with Ewing sarcoma that recurred after initial therapy, which included high-dose therapy with autologous stem cell rescue, were less likely to achieve a second complete remission (cited Ferrari et al. as reference 6 and level of evidence 3iiDiii).
Added Rasper et al. as reference 18 and level of evidence 3iiA.
Added text about how most published reports about the use of high-dose therapy and stem cell support for patients with high-risk Ewing sarcoma have significant flaws in methodology, the most common error being the comparison of this patient group with an inappropriate control group.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.